These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 36520864)

  • 1. Using machine learning to study the effect of medication adherence in Opioid Use Disorder.
    Warren D; Marashi A; Siddiqui A; Eijaz AA; Pradhan P; Lim D; Call G; Dras M
    PLoS One; 2022; 17(12):e0278988. PubMed ID: 36520864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Duration of medication treatment for opioid-use disorder and risk of overdose among Medicaid enrollees in 11 states: a retrospective cohort study.
    Burns M; Tang L; Chang CH; Kim JY; Ahrens K; Allen L; Cunningham P; Gordon AJ; Jarlenski MP; Lanier P; Mauk R; McDuffie MJ; Mohamoud S; Talbert J; Zivin K; Donohue J
    Addiction; 2022 Dec; 117(12):3079-3088. PubMed ID: 35652681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prior use of medications for opioid use disorder in ED patients with opioid overdose: prevalence, misuse and overdose severity.
    Shastry S; Nobel I; Allen LR; Richardson LD; Vidal K; Manini AF
    Am J Emerg Med; 2022 Jan; 51():114-118. PubMed ID: 34735968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioid Overdose After Medication for Opioid Use Disorder Initiation Following Hospitalization or ED Visit.
    Weiner SG; Little K; Yoo J; Flores DP; Hildebran C; Wright DA; Ritter GA; El Ibrahimi S
    JAMA Netw Open; 2024 Jul; 7(7):e2423954. PubMed ID: 39037812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between treatment setting and outcomes among oregon medicaid patients with opioid use disorder: a retrospective cohort study.
    Hartung DM; Markwardt S; Johnston K; Geddes J; Baker R; Leichtling G; Hildebran C; Chan B; Cook RR; McCarty D; Ghitza U; Korthuis PT
    Addict Sci Clin Pract; 2022 Aug; 17(1):45. PubMed ID: 35986384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment for opioid use disorder in the Florida medicaid population: Using a cascade of care model to evaluate quality.
    Johnson K; Hills H; Ma J; Brown CH; McGovern M
    Am J Drug Alcohol Abuse; 2021 Mar; 47(2):220-228. PubMed ID: 33054435
    [No Abstract]   [Full Text] [Related]  

  • 7. An explainable machine learning framework for predicting the risk of buprenorphine treatment discontinuation for opioid use disorder among commercially insured individuals.
    Al Faysal J; Noor-E-Alam M; Young GJ; Lo-Ciganic WH; Goodin AJ; Huang JL; Wilson DL; Park TW; Hasan MM
    Comput Biol Med; 2024 Jul; 177():108493. PubMed ID: 38833799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations Between Inpatient Induction on Medications for Opioid Use Disorder and Postdischarge Medications for Opioid Use Disorder Adherence, Overdose, and Service Use.
    Noam KR; Schmutte TJ; Pirard S; Bourdon C; Langless D; Plant R
    J Addict Med; 2023 May-Jun 01; 17(3):e199-e201. PubMed ID: 37267183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of clinic switching and continuity of medication for opioid use disorder in a Medicaid-enrolled population.
    Cole ES; Drake C; DiDomenico E; Sharbaugh M; Kim JY; Nagy D; Cochran G; Gordon AJ; Gellad WF; Pringle J; Warwick J; Chang CH; Kmiec J; Kelley D; Donohue JM
    Drug Alcohol Depend; 2021 Apr; 221():108633. PubMed ID: 33631544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of the implementation of medication for opioid use disorder and COVID-19 in a statewide correctional system on treatment engagement, postrelease continuation of care, and overdose.
    Klemperer EM; Wreschnig L; Crocker A; King-Mohr J; Ramniceanu A; Brooklyn JR; Peck KR; Rawson RA; Evans EA
    J Subst Use Addict Treat; 2023 Sep; 152():209103. PubMed ID: 37311520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "Sick and tired of being sick and tired": Exploring initiation of medications for opioid use disorder among people experiencing homelessness.
    Swartz N; Adnan T; Peréa F; Baggett TP; Chatterjee A
    J Subst Abuse Treat; 2022 Jul; 138():108752. PubMed ID: 35277306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid Use Disorder and Overdose in the First Year Postpartum: A Rapid Scoping Review and Implications for Future Research.
    Frankeberger J; Jarlenski M; Krans EE; Coulter RWS; Mair C
    Matern Child Health J; 2023 Jul; 27(7):1140-1155. PubMed ID: 36840785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019".
    Krawczyk N; Rivera BD; Jent V; Keyes KM; Jones CM; Cerdá M
    Int J Drug Policy; 2022 Dec; 110():103786. PubMed ID: 35934583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developing a cascade of care for opioid use disorder among individuals in jail.
    Ray B; Victor G; Cason R; Hamameh N; Kubiak S; Zettner C; Dunnigan M; Comartin E; Costello M
    J Subst Abuse Treat; 2022 Jul; 138():108751. PubMed ID: 35241352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "They make it too hard and too many hoops to jump": system and organizational barriers to drug treatment during epidemic rates of opioid overdose.
    Dickson-Gomez J; Krechel S; Ohlrich J; Montaque HDG; Weeks M; Li J; Havens J; Spector A
    Harm Reduct J; 2024 Feb; 21(1):52. PubMed ID: 38413972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duration of medication for opioid use disorder during pregnancy and postpartum by race/ethnicity: Results from 6 state Medicaid programs.
    Austin AE; Durrance CP; Ahrens KA; Chen Q; Hammerslag L; McDuffie MJ; Talbert J; Lanier P; Donohue JM; Jarlenski M
    Drug Alcohol Depend; 2023 Jun; 247():109868. PubMed ID: 37058829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilization of Medications for Opioid Use Disorder Across US States: Relationship to Treatment Availability and Overdose Mortality.
    Krawczyk N; Jent V; Hadland SE; Cerdá M
    J Addict Med; 2022 Jan-Feb 01; 16(1):114-117. PubMed ID: 35120067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Provider perceptions of medication for opioid used disorder (MOUD): A qualitative study in communities with high opioid overdose death rates.
    Paul N; Kennedy AJ; Taubenberger S; Chang JC; Hacker K
    Subst Abus; 2022; 43(1):742-748. PubMed ID: 35100094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioid overdose survivors: Medications for opioid use disorder and risk of repeat overdose in Medicaid patients.
    Crystal S; Nowels M; Samples H; Olfson M; Williams AR; Treitler P
    Drug Alcohol Depend; 2022 Mar; 232():109269. PubMed ID: 35038609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.